Terns Pharmaceuticals
TERN
TERN was delisted on the 4th of May, 2026.
42 hedge funds and large institutions have $394M invested in Terns Pharmaceuticals in 2021 Q1 according to their latest regulatory filings, with 42 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
74.7% more ownership
Funds ownership: 0% → 74.7% (+75%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
+$83.1M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$63.3M |
| 3 |
VC
Vivo Capital
Palo Alto,
California
|
+$58.6M |
| 4 |
DM
Deerfield Management
New York
|
+$51.4M |
| 5 |
SCM
Suvretta Capital Management
New York
|
+$24.7M |
Top Sellers
TERN Hedge Fund Activity: Q1 2021 in Review
42 of the 5,696 institutional investors tracked by Wall St. Rank reported a position in Terns Pharmaceuticals (TERN) for Q1 2021, worth a combined $394M.
Buyers outnumbered sellers: 42 funds opened new TERN positions and 0 closed out — a net gain of 42 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was OrbiMed, opening a new position worth an estimated $83.1M.
- 42 institutional investors held Terns Pharmaceuticals (TERN) as of Q1 2021, up from 0 in Q4 2020.
- Funds reported $394M of Terns Pharmaceuticals stock for Q1 2021.
- 42 funds opened new Terns Pharmaceuticals positions in Q1 2021 and 0 closed out, a net change of +42 holders.
- The largest Terns Pharmaceuticals buyer in Q1 2021 was OrbiMed, an estimated $83.1M added.
Based on aggregated 13F filings for Q1 2021.